Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Symptoms

Multiple Myeloma Epidemiology

Multiple Myeloma Pathophysiology

Management of Myeloma

Multiple Myeloma Imaging Strategies

Multiple Myeloma Treatment

Multiple Myeloma Diagnosis

Latest Multiple Myeloma News and Research

New AI model brings precision medicine to multiple myeloma care

C. Ola Landgren, M.D., Ph.D., received HealthTree Foundation's prestigious 2025 Innovation Award for his work in developing CORAL, a new research tool that leverages AI to predict individual outcomes and guide treatment decisions in patients with multiple myeloma.

19 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

Longest survival in the world reported to date for multiple myeloma patients

Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal Haematologica.

19 Nov 2025

Research identifies factors for long-term myeloma remission

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.

13 Nov 2025

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms — pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination.

31 Oct 2025

Advances in diagnosis and management of systemic light chain amyloidosis

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues and organs, leading to progressive structural and functional impairment.

30 Oct 2025

Novel computational platform can design synthetic protein receptors from scratch

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), have revolutionized cancer treatment.

28 Oct 2025

Common chemical tetrachloroethylene may be harmful to the liver

Liver disease is usually caused by one of three factors: alcohol consumption, fat buildup in the liver linked to obesity, diabetes and high cholesterol, or hepatitis B and C.

23 Oct 2025

Epigenetic editing enables safer and more effective T cell therapies

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary human T cells, addressing a key manufacturing and scalability challenge in next-generation cell therapies.

21 Oct 2025

UPR modulators show promise in treating cancer-related bone disease

Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate conformation.

25 Sep 2025

Blocking iron-regulating enzyme triggers cancer cell death in multiple myeloma

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies against the disease.

24 Sep 2025

Fat distribution appears to influence cancer risk

How fat is distributed in people's bodies could make a difference to their risk of certain cancers, according to new research led by the University of Bristol. The international study is published in the Journal of the National Cancer Institute (JNCI) today [24 September].

23 Sep 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

Triple negative breast cancer exploits lymph node niches to block immune defense

In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease.

16 Sep 2025

Plant-derived carotenoid found to boost immune response against cancer

In a new study, researchers from the University of Chicago discovered that zeaxanthin, a plant-derived carotenoid best known for protecting vision, may also act as an immune-boosting compound by strengthening the cancer-fighting activity of immune cells.

2 Sep 2025